Form D · Biotechnology

Addex Therapeutics Ltd.

Geneva, V8 · CIK 0001574232

Offering snapshot reported Apr 13, 2023 · SEC filing

Reported sold
$3.73M
Offering amount: $3.73M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 5, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 13, 2023Initial$3,733,334No comparison1SEC filing
Aug 4, 2022Initial$4,230,500No comparison1SEC filing
Dec 21, 2021Initial$5,935,118No comparison1SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-478677
Represents amounts received in respect of pre-funded warrants and amounts receivable upon full-exercise of such warrants and other to purchase ADS; such warrants have not yet been exercised.

Source: Form D, filed Apr 13, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Timothy Dyer Director, Executive
Raymond Hill Director
Mikhail Kalinichev Executive
Vincent Lawton Director
Robert Lutjens Executive
Isaac Manke Director
Roger Mills Director, Executive
Jake Nunn Director
Jean Philippe Rocher Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Chemin Des Mines 9
Geneva, V8, CH-1202